Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial EP News Bureau Oct 29, 2026 The TRANSCEND-T2D-2 trial found greater reductions in A1C, body weight and certain cardiovascular risk factors with retatrutide at…
